Please use this identifier to cite or link to this item:
Title: Optimizing care for younger women with hormone receptor‐positive, HER2‐negative metastatic breast cancer.
Authors: de Boer, Richard
Other Authors: Hui, Rina
Lim, Elgene
Yeo, Belinda
Zdenkowski, Nicholas
Keywords: CDK4/6 inhibitor
Endocrine Therapy
Hormone Receptor-positive
Metastatic Breast Cancer
Breast Neoplasms
Multidisciplinary Care
Younger Women
Premenopausal Women
Perimenopausal Women
Supportive Care
Receptors, Estrogen
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Nov-2020
Publisher: Wiley
Citation: Asia Pac J Clin Oncol . 2020 Nov;16 Suppl 5:3-14
Abstract: Treatment strategies for hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negative (HER2–) metastatic breast cancer in young women (<40 years at diagnosis) have traditionally been extrapolated from data obtained from trials conducted either exclusively or predominantly in the postmenopausal setting. These young patients are usually treated with ovarian function suppression (OFS) + endocrine therapy (ET) ± targeted therapy, except if there is a concern about endocrine resistance or a need to gain rapid disease control due to the onset of visceral crisis. This review examines evidence that supports the use of a cyclin‐dependent kinase 4/6 inhibitor, in combination with OFS and ET, when treating premenopausal or perimenopausal women with HR+/HER2– metastatic breast cancer. This includes data from the MONALEESA‐7 study (treating only premenopausal/perimenopausal women in the first‐line setting), and the results of subgroup analyses from the PALOMA‐3 and MONARCH‐2 trials. We also consider a number of age‐specific challenges that younger breast cancer patients can face, highlighting the importance of a multidisciplinary approach to ongoing care.
DOI: 10.1111/ajco.13461
PubMed URL:
ISSN: 1743-7563
Journal Title: Asia-Pacific Journal of Clinical Oncology
Type: Journal Article
Affiliated Organisations: University of Sydney, Camperdown, Sydney, New South Wales, Australia
Westmead Hospital, Westmead, Sydney, New South Wales, Australia
St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Sydney, New South Wales, Australia
Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
Austin Health, Heidelberg, Melbourne, Victoria, Australia
Olivia Newton‐John Cancer Research Institute, Heidelberg, Melbourne, Victoria, Australia
University of Newcastle, Newcastle, New South Wales, Australia
Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia
Breast Cancer Trials, Newcastle, New South Wales, Australia
Type of Clinical Study or Trial: Review
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.